Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Disposition of [¹⁴C]-LY3202626 in Healthy Male Subjects
NCT02555449Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2015
- Primary completion
- Nov 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of LY3202626 in Alzheimer's disease (AD), sponsored by Eli Lilly and Company. Primary endpoints: Fecal Excretion of Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered and Urinary Excretion of Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered. Started Sep 2015; status: completed.
02
Drugs
LY3202626
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02555449.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02555449.